News Sosei see Teva pipeline cull as an opportunity Troubled generics giant Teva is continuing the heavy pruning of its business and has cut a novel migraine drug from its pipeline.
UK & Europe Ex-Teva exec to be new Hikma CEO Hikma has a new chief executive after Said Darwazah, the son of the company’s late founder, Samih Darwazah, stepped aside.
News Novartis/Amgen migraine drug reduces attacks after others fa... Aimovig notches up another late-stage trial success
News AZ's cancer and respiratory drugs approved in Japan Two AstraZeneca (AZ) drugs have been approved in Japan – its cancer drug Lynparza and its respiratory drug Fasenra.
News NHS funding for five MS drugs under threat NICE calls for further discounts on beta-interferons and Copaxone
News Teva's huge cutbacks to slash workforce by 25%, close R&D si... Teva has announced a massive restructuring of its business, with 14,000 jobs to be cut, and R&D operations and regional headquarters to be closed around the world.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
